Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human, Bovine, Chinese Hamster

Applications

Validated:

Immunohistochemistry, Western Blot, Blockade of Receptor-ligand Interaction, Flow Cytometry, CyTOF-ready

Cited:

Immunohistochemistry, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen, Western Blot, Neutralization, Flow Cytometry, Immunocytochemistry, Blocking, Functional Assay, Proximity Ligation Assay (PLA)

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG
View all VEGFR1/Flt-1 Primary Antibodies »

Product Specifications

Immunogen

S. frugiperda insect ovarian cell line Sf 21-derived recombinant human VEGFR1/Flt-1
Ser27-His687
Accession # NP_001153392

Specificity

Detects human VEGFR1/Flt-1 in direct ELISAs and Western blots.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human VEGFR1/Flt-1 Antibody

VEGFR1/Flt-1 antibody in Human Breast Cancer Tissue by Immunohistochemistry (IHC-P).

VEGFR1/Flt‑1 in Human Breast Cancer Tissue.

VEGFR1/Flt‑1 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using 15 µg/mL Human VEGFR1/Flt‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF321) overnight at 4 °C. Tissue was stained (red) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
VEGFR1/Flt-1 antibody in Human Ovarian Cancer Tissue by Immunohistochemistry (IHC-P).

VEGFR1/Flt‑1 in Human Ovarian Cancer Tissue.

VEGFR1/Flt-1 was detected in immersion fixed paraffin-embedded sections of human ovarian cancer tissue using Human VEGFR1/Flt-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF321) at 3 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; CTS008) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Detection of Human VEGFR1/Flt-1 by Western Blot

Detection of Human VEGFR1/Flt-1 by Western Blot

Exogenous VEGF165 suppresses RASSF1A expression in normal epithelial and endothelial cells. Metastatic colon cancer cells (mCRC, (A) T84 and (B) Colo 205) were stimulated with VEGF165 as indicated before and cell metabolism was performed by MTT assay for 6 h (black dash), 24 h (green) and 48 h (pink). Immortalized benign protate ((C) RWPE1), human bronchial epithelial cells ((D) HBEpc), immortalized human breast epithelial cells ((E) MCF-10A), endothelial cells (F, EC) were stimulated with or without VEGF165 (12.5 and 25 ng/mL) for 24 h. Cell lysates were monitored by Western blot for p-VEGFR1, p-VEGFR2, RASSF1A, and GAPDH as indicated. Immunoblot was quantified by scanning densitometry and normalized against GAPDH expression for RWPE1 (G), HBEpc (H), MCF 10A (I) and EC (lower panel of (F)). Results are from three independent experiments and statistical significance was determined using one way-ANOVA followed Bonferroni test. (* p < 0.05, ** p < 0.01, *** p < 0.001). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/30744076), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human VEGFR1/Flt-1 by Western Blot

Detection of Human VEGFR1/Flt-1 by Western Blot

Exogenous VEGF165 suppresses RASSF1A expression in normal epithelial and endothelial cells. Metastatic colon cancer cells (mCRC, (A) T84 and (B) Colo 205) were stimulated with VEGF165 as indicated before and cell metabolism was performed by MTT assay for 6 h (black dash), 24 h (green) and 48 h (pink). Immortalized benign protate ((C) RWPE1), human bronchial epithelial cells ((D) HBEpc), immortalized human breast epithelial cells ((E) MCF-10A), endothelial cells (F, EC) were stimulated with or without VEGF165 (12.5 and 25 ng/mL) for 24 h. Cell lysates were monitored by Western blot for p-VEGFR1, p-VEGFR2, RASSF1A, and GAPDH as indicated. Immunoblot was quantified by scanning densitometry and normalized against GAPDH expression for RWPE1 (G), HBEpc (H), MCF 10A (I) and EC (lower panel of (F)). Results are from three independent experiments and statistical significance was determined using one way-ANOVA followed Bonferroni test. (* p < 0.05, ** p < 0.01, *** p < 0.001). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/30744076), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human VEGFR1/Flt-1 by Western Blot

Detection of Human VEGFR1/Flt-1 by Western Blot

Exogenous VEGF165 suppresses RASSF1A expression in normal epithelial and endothelial cells. Metastatic colon cancer cells (mCRC, (A) T84 and (B) Colo 205) were stimulated with VEGF165 as indicated before and cell metabolism was performed by MTT assay for 6 h (black dash), 24 h (green) and 48 h (pink). Immortalized benign protate ((C) RWPE1), human bronchial epithelial cells ((D) HBEpc), immortalized human breast epithelial cells ((E) MCF-10A), endothelial cells (F, EC) were stimulated with or without VEGF165 (12.5 and 25 ng/mL) for 24 h. Cell lysates were monitored by Western blot for p-VEGFR1, p-VEGFR2, RASSF1A, and GAPDH as indicated. Immunoblot was quantified by scanning densitometry and normalized against GAPDH expression for RWPE1 (G), HBEpc (H), MCF 10A (I) and EC (lower panel of (F)). Results are from three independent experiments and statistical significance was determined using one way-ANOVA followed Bonferroni test. (* p < 0.05, ** p < 0.01, *** p < 0.001). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/30744076), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of VEGFR1/Flt-1 in HUVEC cells by Flow Cytometry

HUVEC cells were stained with Goat Anti-Human VEGFR1/Flt-1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF321, filled histogram) or isotype control antibody (Catalog # AB-108-C, open histogram) followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0108). View our protocol for Staining Membrane-associated Proteins.
Detection of Human VEGFR1/Flt-1 by Western Blot

Detection of Human VEGFR1/Flt-1 by Western Blot

VEGFR1 isoforms in human degenerated and bovine healthy discs. A representative immunoblotting assay showed the expression of the full-length membrane form (~ 200 kDa), the soluble form (~ 130 kDa) and a cytoplasmic fragment (~ 60 kDa) in human degenerated (a) and healthy bovine (c) disc cells. beta -Actin was used as control. Western blot quantification of membrane and soluble VEGFR1 was performed on human (b; n = 3) and bovine (d; n = 2) disc cells. Results represent an average of area (square pixels) ± SD normalized on beta Actin. White bars represent AF, grey bars NP. No statistical significance with non-parametric Mann–Whitney–Wilcoxon U test for independent variables Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/29784013), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of VEGFR1/Flt-1 by Western Blot

Detection of VEGFR1/Flt-1 by Western Blot

Decreased levels of VEGFR-2 in hypoxia and in early first trimester placentae.A: Representative VEGFR-2 and sFlt-1 immunoblots of placental villous explants cultured at 3% and 20% O2. Densitometry analysis comparing normalized VEGFR-2 immunoreactivity between explants cultured at 3% (n = 7) and 20% O2 (n = 7). VEGFR-2 transcript levels were assessed by qPCR analysis comparing 3% (n = 4) and 20% O2 (n = 4) samples. B: Representative VEGFR-2 immunoblots of early (EFT) and late (LFT) first trimester placentae. Densitometry analysis comparing normalized VEGFR-2 immunoreactivity between samples were not significantly different. Transcript levels were assessed by qPCR analysis comparing VEGFR-2 levels in EFT and LFT placentae. (EFT, n = 12; LFT, n = 14; *P<0.05). All values are represented as the means±SEM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/24260556), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of VEGFR1/Flt-1 by Western Blot

Detection of VEGFR1/Flt-1 by Western Blot

sFlt-1 directly attenuates VEGFR-2 expression and downstream signalling in placental villous explants.A: Representative VEGFR-2, sFlt-1, pAkt and pERK immunoblots of first trimester placental villous explants treated with sFlt-1 or a blocking antibody to sFlt-1. Densitometry analyses comparing normalized VEGFR-2, sFlt-1, pAkt and pERK in treated samples (Con, control; sFlt-1, sFlt-1 protein; alpha -Flt, Flt-1 neutralizing antibody; n = 3, *P<0.05). All values are represented as the means±SEM. B: Representative VEGFR-2 immunoblot of first trimester placental villous explants treated with VEGF. Densitometry analyses comparing normalized VEGFR-2 between control and VEGF-treated samples (Con, control; VEGF, VEGF-treated; n = 3, *P<0.05). All values are represented as the means±SEM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/24260556), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of VEGFR1/Flt-1 by Western Blot

Detection of VEGFR1/Flt-1 by Western Blot

An inverse correlation between VEGFR-2 and sFlt-1 levels in preeclamptic placentae.A: Representative VEGFR-2 and sFlt-1 immunoblots of PE and PTC placentae. Densitometry analysis comparing normalized VEGFR-2 immunoreactivity between PE (n = 13) and PTC (n = 8) samples. VEGFR-2 transcript levels were assessed by qPCR analysis comparing PE (n = 12) and PTC (n = 7) samples. B: Representative VEGFR-2 and sFlt-1 immunoblots of placental tissues from PE and control (Con) dichorionic twins. (PE, preeclampsia; PTC, age-matched preterm control; *P<0.05). All values are represented as the means±SEM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/24260556), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of VEGFR1/Flt-1 by Western Blot

Detection of VEGFR1/Flt-1 by Western Blot

An inverse correlation between VEGFR-2 and sFlt-1 levels in preeclamptic placentae.A: Representative VEGFR-2 and sFlt-1 immunoblots of PE and PTC placentae. Densitometry analysis comparing normalized VEGFR-2 immunoreactivity between PE (n = 13) and PTC (n = 8) samples. VEGFR-2 transcript levels were assessed by qPCR analysis comparing PE (n = 12) and PTC (n = 7) samples. B: Representative VEGFR-2 and sFlt-1 immunoblots of placental tissues from PE and control (Con) dichorionic twins. (PE, preeclampsia; PTC, age-matched preterm control; *P<0.05). All values are represented as the means±SEM. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/24260556), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human VEGFR1/Flt-1 by Western Blot

Detection of Human VEGFR1/Flt-1 by Western Blot

Effect of the metalloprotease inhibitors, GM6001 and TAPI-1 on Flt1 N-terminal cleavage. Panel A: HUVECs were incubated with GM6001 (10 µg/ml) and PMA (30 nM) for the indicated times. GM6001 significantly reduces the PMA-induced soluble Flt1 levels measured by ELISA in conditioned media (CM). **p<0.001 and *p<0.05, n = 3. Panel B and C: HEK293 cells transiently expressing HA and Flag-tagged Flt1 were treated with metalloproteases inhibitors, GM6001 (10 µg/ml) and TAPI-1 (20 µM) and conditioned media was immunoblotted with HA, the epitope tag at the N-terminal end of Flt1 or with AF321, an antibody that recognizes the N-terninus of Flt1 and/or sFlt1. Both GM6001 and TAPI-1 significantly reduces the abundance of the cleaved N-terminal fragment. Representative immunoblot in B and pooled data quantified by densitometry shown in C. **p<0.001 by Kruskal Wallis ANOVAR, Mean ± SE, n = 3–7. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/25387128), licensed under a CC0-1.0 license. Not internally tested by R&D Systems.

Applications for Human VEGFR1/Flt-1 Antibody

Application
Recommended Usage

Blockade of Receptor-ligand Interaction

In a functional ELISA, 1-4 µg/mL of this antibody will block 50% of the binding of 2 ng/mL of Recombinant Human PlGF (Catalog # 264-PG) to immobilized Recombinant Human VEGFR1/Flt-1 Fc Chimera (Catalog # 321-FL) coated at 1 µg/mL (100 µL/well). At 30 μg/mL, this antibody will block >90% of the binding.

CyTOF-ready

Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.

Flow Cytometry

0.25 µg/106 cells
Sample: HUVEC human umbilical vein endothelial cells

Immunohistochemistry

5-15 µg/mL
Sample: Immersion fixed paraffin-embedded sections of human breast cancer and ovarian cancer tissues

Western Blot

0.1 µg/mL
Sample: Recombinant Human VEGFR1/Flt‑1 Fc Chimera (Catalog # 321-FL)

Reviewed Applications

Read 7 reviews rated 4.6 using AF321 in the following applications:

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

  • Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
  • Spillover Popups - Visualize the spectra of individual fluorochromes
  • Antigen Density Selector - Match fluorochrome brightness with antigen density
Build Your Panel Now
Flow Cytometry

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
*Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: VEGFR1/Flt-1

Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) is a receptor tyrosine kinase that is expressed primarily on endothelial cells and plays a role in vasculogenesis and angiogenesis. A soluble variant of VEGFR1 was also reported to bind VEGF and PlGF with high affinity and function as a potent VEGF antagonist.

Long Name

Vascular Endothelial Growth Factor Receptor 1

Alternate Names

Flt-1, FLT1, FRT, VEGF R1, VEGFR-1

Entrez Gene IDs

2321 (Human); 14254 (Mouse)

Gene Symbol

FLT1

UniProt

NP_001153392

Additional VEGFR1/Flt-1 Products

Product Documents for Human VEGFR1/Flt-1 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human VEGFR1/Flt-1 Antibody

For research use only

Citations for Human VEGFR1/Flt-1 Antibody

Customer Reviews for Human VEGFR1/Flt-1 Antibody (7)

4.6 out of 5
7 Customer Ratings
5 Stars
57%
4 Stars
43%
3 Stars
0%
2 Stars
0%
1 Stars
0%

Have you used Human VEGFR1/Flt-1 Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Customer Images

Showing  1 - 5 of 7 reviews Showing All
Filter By:
Clear Filters X
  • Human VEGFR1/Flt-1 Antibody
    Name: Anonymous
    Application: Immunohistochemistry
    Sample Tested: Embryonic retina
    Species: Mouse
    Verified Customer | Posted 05/25/2024
    Human VEGFR1/Flt-1 Antibody AF321
  • Human VEGFR1/Flt-1 Antibody
    Name: Anonymous
    Application: Western Blot
    Sample Tested: HUVEC human umbilical vein endothelial cells
    Species: Human
    Verified Customer | Posted 03/24/2021
    Human VEGFR1/Flt-1 Antibody AF321
  • Human VEGFR1/Flt-1 Antibody
    Name: Anonymous
    Application: Immunocytochemistry/Immunofluorescence
    Sample Tested: HUVEC human umbilical vein endothelial cells
    Species: Human
    Verified Customer | Posted 03/24/2021
    Human VEGFR1/Flt-1 Antibody AF321
  • Human VEGF R1/Flt-1 Antibody
    Name: Tamar Licht
    Application: Immunocytochemistry/Immunofluorescence
    Sample Tested: Embryonic brain
    Species: Mouse
    Verified Customer | Posted 08/08/2018
    transgenic mouse line -conditional induction of human sFlt1
    Human VEGFR1/Flt-1 Antibody AF321
  • Human VEGF R1/Flt-1 Antibody
    Name: Anonymous
    Application: Immunocytochemistry/Immunofluorescence
    Sample Tested: CT26 mouse colorectal cancer cell line and Human liver cancer cell line
    Species: Human
    Verified Customer | Posted 07/08/2016
  • Name: Anonymous
    Application: Flow Cytometry
    Sample Tested: See PMID 19757485
    Species: Human
    Verified Customer | Posted 01/07/2015
  • Name: Anonymous
    Application: Western Blot
    Sample Tested: See PMID 21699503
    Species: Human
    Verified Customer | Posted 01/07/2015

There are no reviews that match your criteria.

Showing  1 - 5 of 7 reviews Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies